Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 480

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Open access
Boorjian, Stephen A, Alemozaffar, Mehrdad, Konety, Badrinath R, Shore, Neal D, Gomella, Leonard G, Kamat, Ashish M, Bivalacqua, Trinity J, Montgomery, Jeffrey S, Lerner, Seth P, Busby, Joseph E, Poch, Michael, Crispen, Paul L, Steinberg, Gary D, Schuckman, Anne K, Downs, Tracy M, Svatek, Robert S, Mashni, Joseph, Lane, Brian R, Guzzo, Thomas J, Bratslavsky, Gennady, Karsh, Lawrence I, Woods, Michael E, Brown, Gordon, Canter, Daniel, Luchey, Adam, Lotan, Yair, Krupski, Tracey, Inman, Brant A, Williams, Michael B, Cookson, Michael S, Keegan, Kirk A, Andriole, Gerald L, Sankin, Alexander I, Boyd, Alan, O'Donnell, Michael A, Sawutz, David, Philipson, Richard, Coll, Ruth, Narayan, Vikram M, Treasure, F Peter, Yla-Herttuala, Seppo, Parker, Nigel R, Dinney, Colin P N·2021·The Lancet Oncology

Abstract

Summary Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer. Methods In this phase 3, multicentre, open-label, repeat-dose study done in 33 centres (hospitals and clinics) in the USA, we recruited patients aged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncology Group status of 2 or less. Patients were excluded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymphovascular invasion, micropapillary disease, or hydronephrosis. Eligible patients received a single intravesical 75 mL dose of nadofaragene firadenovec (3 × 10¹¹ viral particles per mL). Repeat dosing at months 3, 6, and 9 was done in the absence of high-grade recurrence. The primary endpoint was complete response at any time in patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour). The null hypothesis specified a complete response rate of less than 27% in this cohort. Efficacy analyses were done on the per-protocol population, to include only patients strictly meeting the BCG-unresponsive definition. Safety analyses were done in all patients who received at least one dose of treatment. The study is ongoing, with a planned 4-year treatment and monitoring phase. This study is registered with ClinicalTrials.gov, NCT02773849. Findings Between Sept 19, 2016, and May 24, 2019, 198 patients were assessed for eligibility. 41 patients were excluded, and 157 were enrolled and received at least one dose of the study drug. Six patients did not meet the definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore excluded from efficacy analyses; the remaining 151 patients were included in the per-protocol efficacy analyses. 55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths. Interpretation Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state. Funding FKD Therapies Oy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30540-4

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 480

Metadata

Authors
Boorjian, S. A., Alemozaffar, M., Konety, B. R., Shore, N. D., Gomella, L. G., Kamat, A. M., Bivalacqua, T. J., Montgomery, J. S., Lerner, S. P., Busby, J. E., Poch, M., Crispen, P. L., Steinberg, G. D., Schuckman, A. K., Downs, T. M., Svatek, R. S., Mashni, J., Lane, B. R., Guzzo, T. J., Bratslavsky, G., Karsh, L. I., Woods, M. E., Brown, G., Canter, D., Luchey, A., Lotan, Y., Krupski, T., Inman, B. A., Williams, M. B., Cookson, M. S., Keegan, K. A., Andriole, G. L., Sankin, A. I., Boyd, A., O'Donnell, M. A., Sawutz, D., Philipson, R., Coll, R., Narayan, V. M., Treasure, F. P., Yla-Herttuala, S., Parker, N. R., & Dinney, C. P. N.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-01
Volume
22
Issue
1
Pages
107-117
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3108799736
Cited by
480
References
12
FWCI
36.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30540-4
The paper
Boorjian, S. A., Alemozaffar, M., Konety, B. R., Shore, N. D., Gomella, L. G., Kamat, A. M., Bivalacqua, T. J., Montgomery, J. S., Lerner, S. P., Busby, J. E., Poch, M., Crispen, P. L., Steinberg, G. D., Schuckman, A. K., Downs, T. M., Svatek, R. S., Mashni, J., Lane, B. R., Guzzo, T. J., . . . Dinney, C. P. N. (2021). Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30540-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.